Moderna, Inc. has announced impressive financial results for the third quarter of 2026, showcasing a significant increase in revenue and net income. The company's performance reflects a successful strategy in the competitive biological products industry, particularly following the recent approvals of its products.

On November 6, 2026, Moderna reported a revenue of $1.3 billion for Q3, a 29% increase from the same period last year. The company also achieved a GAAP net income of $162 million, a substantial turnaround from a net loss of $200 million in Q3 2025. This performance has led Moderna to revise its revenue growth expectations for the year, now forecasting an increase of 15% to 25%, up from the previous estimate of 10%.

Background

Moderna, Inc. is a leading biotechnology company focused on developing and commercializing messenger RNA (mRNA) therapeutics and vaccines. The company operates under the SIC code 2836, which pertains to biological products (no diagnostic substances). Moderna trades on the Nasdaq under the ticker symbol MRNA and is classified as a large accelerated filer.

What the Filing Says

The filing reveals key financial metrics from the third quarter, including:

  • Total revenue of $1.3 billion, compared to $1.0 billion in Q3 2025.
  • GAAP net income of $162 million, a significant improvement from a net loss of $200 million in the prior year.
  • Increased revenue growth outlook for 2026, now expected to be between 15% and 25%.
  • GAAP diluted earnings per share of $0.38.

Moderna's Chief Executive Officer, Stéphane Bancel, stated, “We delivered 29% revenue growth in the third quarter, alongside the U.S. approval of mFLUSIVA, our fifth approved product globally, and positive Phase 3 results for intismeran in melanoma.”

Impact

This financial performance may significantly impact Moderna's stakeholders, including investors, employees, and partners in the biotechnology sector. The increase in revenue and net income could enhance investor confidence and attract potential partnerships, as well as influence competitors within the biological products industry to improve their offerings and financial health.

What's Next

Looking ahead, Moderna anticipates further developments in its pipeline, including additional readouts for intismeran and pivotal data related to propionic acidemia. The filing does not specify any immediate next steps following this report.

For more details, the full press release is available as Exhibit 99.1 in the SEC filing (accession number 0001682852-26-000194).